Ponatinib (Iclusig) is a potent multi-targeted tyrosine kinase inhibitor primarily indicated for the treatment of patients with chronic phase (CP), accelerated phase (AP), and blast phase (BP) chronic myeloid leukemia (CML), Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), as well as those harboring the T315I mutation, who are resistant or intolerant to previous tyrosine kinase inhibitors (TKIs).
What are the Precautions for Taking Ponatinib (Iclusig)?
1. Contraindicated Populations
Patients with a known hypersensitivity to any component of ponatinib.
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP-CML).
Patients with uncontrolled hypertension, hypertriglyceridemia, diabetes mellitus, or active cardiovascular disease require careful assessment before initiating treatment.
2. Administration Method
Swallow the tablet whole. Do not crush, chew, or split the tablet.
The tablet can be taken with or without food.
If a dose is missed, do not make up for the missed dose; take the next scheduled dose as planned.
3. Warning for Severe Adverse Reactions
Vascular Occlusive Events (VOEs): May cause myocardial infarction, stroke, peripheral vascular disease, and may even require emergency revascularization.
Heart Failure: New-onset or worsening heart failure requires immediate intervention.
Hepatotoxicity: May progress to liver failure; regular monitoring of liver function is necessary.
Pancreatitis and Hyperlipasemia: Pancreatitis occurs in 34% of patients (median time to onset: 8 days), and assessment should be conducted in combination with clinical symptoms.
4. Drug Interactions
Strong CYP3A Inhibitors: Concomitant use should be avoided. If co-administration is deemed necessary, the dose of ponatinib must be reduced (e.g., from 45 mg to 30 mg).
Strong CYP3A Inducers: May decrease the plasma concentration of ponatinib; concomitant use should be avoided or close monitoring of treatment efficacy is required.
Medication Monitoring for Ponatinib (Iclusig)
1. Baseline Assessment and Regular Checks
Confirm the BCR::ABL1 mutation status (especially the T315I mutation).
Monitor blood pressure, electrocardiogram (ECG), liver function, complete blood count (CBC), and serum lipase levels.
2. Monitoring for Vascular Events
Monitor for symptoms such as chest pain, dyspnea, localized limb swelling, or neurological deficits.
Adjust the dose based on the severity of the event (e.g., permanent discontinuation is required for grade 3-4 arterial occlusion).
3. Tracking of Laboratory Indicators
Liver Function: Measure alanine aminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin every 3 weeks.
Pancreatic Function: Measure serum lipase every 2 weeks for the first 2 months of treatment, then monthly thereafter.
Complete Blood Count (CBC): Conduct tests every 2 weeks for the first 3 months, then monthly thereafter. Pay close attention to changes in neutrophils (<1×10⁹/L) and platelets (<50×10⁹/L).
4. Other Examinations
Fundus Examination: Perform at baseline and once every quarter.
Blood Pressure Monitoring: Conduct at each follow-up visit.
